MX2021015711A - Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares. - Google Patents

Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares.

Info

Publication number
MX2021015711A
MX2021015711A MX2021015711A MX2021015711A MX2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A MX 2021015711 A MX2021015711 A MX 2021015711A
Authority
MX
Mexico
Prior art keywords
prevotella
histicola
melaninogenica
copd
pulmonary disease
Prior art date
Application number
MX2021015711A
Other languages
English (en)
Spanish (es)
Inventor
Veena Taneja
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2021015711A publication Critical patent/MX2021015711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2021015711A 2019-06-17 2020-06-17 Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares. MX2021015711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862186P 2019-06-17 2019-06-17
PCT/US2020/038084 WO2020257248A1 (en) 2019-06-17 2020-06-17 Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions

Publications (1)

Publication Number Publication Date
MX2021015711A true MX2021015711A (es) 2022-02-03

Family

ID=74037580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015711A MX2021015711A (es) 2019-06-17 2020-06-17 Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares.

Country Status (11)

Country Link
US (1) US20220296657A1 (https=)
EP (1) EP3983067A4 (https=)
JP (1) JP2022537178A (https=)
KR (1) KR20220024466A (https=)
CN (1) CN114340732A (https=)
AU (1) AU2020295393A1 (https=)
BR (1) BR112021025416A2 (https=)
CA (1) CA3143597A1 (https=)
CO (1) CO2022000029A2 (https=)
MX (1) MX2021015711A (https=)
WO (1) WO2020257248A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109620A2 (en) * 2018-11-30 2020-06-04 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses
WO2022182707A1 (en) * 2021-02-26 2022-09-01 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2024097250A1 (en) * 2022-10-31 2024-05-10 The Trustees Of Columbia University In The City Of New York Polymeric carrier for probiotics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
AU2004298384A1 (en) * 2003-12-17 2005-06-30 N.V. Nutricia Lactic acid producing bacteria and lung function
MX2009010187A (es) 2007-03-27 2009-10-19 Procter & Gamble Metodos y estuches para administracion de probioticos.
WO2011053653A2 (en) 2009-10-30 2011-05-05 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
JP2014196260A (ja) * 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
EP3679798B1 (en) * 2015-02-03 2021-11-17 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating arthritis
CN108473963A (zh) * 2015-09-09 2018-08-31 雷维维科公司 用于异种移植的多重转基因猪
CN110352237B (zh) * 2017-02-28 2023-01-10 精密生物集团有限公司 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌
WO2019004668A1 (ko) * 2017-06-30 2019-01-03 주식회사 엠디헬스케어 프로테우스 속 세균 유래 나노소포 및 이의 용도
MX2020002660A (es) * 2017-09-08 2020-07-22 Evelo Biosciences Inc Vesiculas extracelulares de prevotella.
WO2020109620A2 (en) * 2018-11-30 2020-06-04 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses

Also Published As

Publication number Publication date
EP3983067A4 (en) 2023-06-14
US20220296657A1 (en) 2022-09-22
JP2022537178A (ja) 2022-08-24
BR112021025416A2 (pt) 2022-02-22
CO2022000029A2 (es) 2022-04-08
CN114340732A (zh) 2022-04-12
CA3143597A1 (en) 2020-12-24
WO2020257248A1 (en) 2020-12-24
EP3983067A1 (en) 2022-04-20
AU2020295393A1 (en) 2022-01-06
KR20220024466A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2021015711A (es) Preparaciones de prevotella y tratamiento de enfermedad pulmonar obstructiva cronica (epoc) y otras afecciones pulmonares.
MY209319A (en) Compounds useful to treat influenza virus infections
SA520420287B1 (ar) مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها
ZA202204929B (en) Rimegepant for cgrp related disorders
CR20220609A (es) Antagonistas del receptor de lpa y usos de los mismos
MX2020009000A (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido.
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EP4527461A3 (en) A compound, compositions thereof and this compound for use in methods of treating cns disorders
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12021550368A1 (en) Dimethyl amino azetidine amides as jak inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CL2019003393A1 (es) Virus oncolíticos y método.
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EP4252755A3 (en) Therapeutic compounds
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
PH12018550102A1 (en) Methods and compositions for treating hunter syndrome